FDA moves to cut expert panel input on new drugs

Becker’s Hospital Review – Friday, September 12, 2025
By Alexandra Murphy

The FDA is moving to scale back its long-standing use of expert panels to review drug applications, KFF Health News reported Sept. 12.

George Tidmarsh, MD, PhD, director of the FDA’s Center for Drug Evaluation and Research, said the agency would prefer to move away from convening advisory committees for individual drug approvals, calling them “redundant” and burdensome for regulators and drugmakers.

Click here to read the entire article.